IMBRUVICA (ibrutinib) has been approved by the FDA as a single, oral agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. The drug was originally approved on November 13, 2013 for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Catalent Pharma Solutions
has been contracted by Pharmacyclics
to provide drug product capsules of IMBRUVICA for commercial supply from its site in Kansas City, MO.